Humanin
Also known as: HN, HNG (S14G-humanin)
Popular For
Neuroprotection, metabolic health, cellular aging
Key Facts: Humanin
- Category
- Anti-Aging
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Extensive animal research
- Administration
- Injection (route varies)
- Typical Dose
- 5-10 mg weekly divided into 2-3 injections
- Frequency
- 2-3x weekly (e.g., Monday, Wednesday, Friday)
- Evidence Level
- Animal Studies
- Duration
- Variable
Mechanism of Action
Humanin acts through multiple pathways including STAT3 signaling, binding to IGFBP-3, and activating the FPRL1 receptor. It protects neurons from apoptosis, improves insulin sensitivity, and has anti-inflammatory effects.
Research Summary
Research shows protection against amyloid-beta toxicity in Alzheimer's models. Studies demonstrate improved insulin sensitivity, reduced atherosclerosis in animal models, and potential anti-aging effects. Human studies are limited.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
5-10 mg weekly divided into 2-3 injections
5-10 mg per week
2-3x weekly (e.g., Monday, Wednesday, Friday)
Subcutaneous injection to abdomen or thigh. Cycle 2-4 weeks on, 2-4 weeks off. Often stacked with MOTS-c and NAD+ for mitochondrial support. Store lyophilized at 0-5°C; reconstituted solution stable 5 days at 4°C or freeze for longer storage.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
Research varies widely
HNG analogs used at higher doses
Duration
Variable
Administration
Injection (route varies)
Timing & Administration
Best Time to Take
Morning
Once daily
Food Recommendation
With or without food
Why This Timing?
Humanin is a mitochondrial peptide. Morning use supports daytime cellular energy demands.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated (preclinical)
- ●Mild injection site reactions
- ●Potential pro-tumoral effects
- ●May affect glucose metabolism
- ●No human clinical trial data
References
Related Peptides
Peptides commonly compared with Humanin or used in similar applications.
FOXO4-DRI
PreclinicalA senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging, including kidney health restoration.
Anti-AgingVesilute
PreclinicalA synthetic dipeptide (Glu-Asp) bioregulator from the Khavinson peptide family, studied for urinary tract and prostate support. Research suggests it may help with bladder function and prostate microcirculation. Part of the tissue-specific bioregulatory compounds developed over 40+ years of research.
Anti-AgingGlutathione
Clinical TrialsThe body's master antioxidant - a tripeptide composed of glutamate, cysteine, and glycine. Found in every cell at concentrations similar to glucose (5mM). Essential for detoxification, immune function, and cellular protection against oxidative stress.
Anti-AgingDSIP
Clinical TrialsA neuropeptide that promotes deep delta wave sleep. First isolated from rabbit brains in 1977. Used for sleep optimization and stress reduction.
Anti-AgingNAD+ Precursors
Clinical TrialsWhile not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
Anti-AgingSS-31
FDAA mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Anti-AgingLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Humanin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.